Return to homepagePandemic Pact

Preclinical development of innovative mRNA / MVAvaccines against SARS-CoV2

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: COV20_00214

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)

  • Principal Investigator

    Felipe García

  • Research Location

    Spain

  • Lead Research Institution

    INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The purpose of this project is to design and test in preclinical studies a new vaccine against SARS-CoV2.The overall objective: 1. In a first step, to test a new mRNA vaccine candidate encoding SARS-CoV2epitopes selected through a bioinformatic approach and co-formulated with nanoparticles (mRNA-CoV2) in vitro and in vivo to assess the potential to induce SARS-CoV2-specific immune responses. 2. In a second step, to test if a prime-boost strategy with mRNA-CoV2 prime and MVA-CoV2 boost induce higher immune responses as compared with mRNA-CoV2 alone.